z-logo
open-access-imgOpen Access
FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction
Author(s) -
Lisa Groß,
Lisa Paintmayer,
Sebastian Lehner,
Lydia Brandl,
Christoph Brenner,
Ulrich Grabmaier,
Bruno Hüber,
Peter Bartenstein,
Hans-Diogenes Theiss,
WolfgangMichael Franz,
Steffen Maßberg,
Andrei Todica,
Stefan Brunner
Publication year - 2015
Publication title -
european heart journal - cardiovascular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.576
H-Index - 92
eISSN - 2047-2412
pISSN - 2047-2404
DOI - 10.1093/ehjci/jev237
Subject(s) - myocardial infarction , medicine , sitagliptin , bone marrow , ligation , cardiology , placebo , ventricular remodeling , ejection fraction , heart failure , pathology , insulin , alternative medicine , metformin
Dual therapy comprising G-CSF for mobilization of bone marrow-derived progenitor cells (BMPCs), with simultaneous pharmacological inhibition of dipeptidylpeptidase-IV for enhanced myocardial recruitment of circulating BMPC via the SDF-1α/CXCR4-axis, has been shown to improve survival after acute myocardial infarction (AMI). Using an innovative method to provide non-invasive serial in vivo measurements and information on metabolic processes, we aimed to substantiate the possible effects of this therapeutic concept on cardiac remodelling after AMI using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom